Department of Medical Biology, Faculty of Health Sciences, University of Tromsø - The Arctic University of Norway, 9037, Tromsø, Norway.
Department of Clinical Dentistry, Faculty of Health Sciences, University of Tromsø - The Arctic University of Norway, 9037, Tromsø, Norway.
Br J Cancer. 2019 Apr;120(7):714-727. doi: 10.1038/s41416-019-0409-6. Epub 2019 Feb 27.
Various immune cells have been suggested as prognostic markers for cancer patients. In this article, we present a systematic review and meta-analysis of studies assessing the prognostic value of tissue-infiltrating immune cells in oral cancer and discuss the reporting quality of these studies.
We performed a systematic literature search and included studies using immunohistochemistry and survival analysis to assess the prognostic value of tumour-infiltrating T cells, B cells, macrophages, dendritic cells, mast cells and natural killer cells in oral cancer. We performed meta-analysis of studies providing necessary statistical data and investigated the studies' adherence to the REporting recommendations for tumour MARKer prognostic studies (REMARK) guidelines.
Of the 1960 articles identified, 33 were eligible for this systematic review and 8 were included in the meta-analysis. CD163+ M2 macrophages and CD57+ natural killer cells were the most promising predictors of survival in oral cancer patients. Many studies lacked important information on their design and conduct.
Deficiencies in the reporting of study design and conduct make it difficult to draw reliable conclusions about the suggested markers. The prognostic value of CD163+ M2 macrophages and CD57+ natural killer cells should be validated in large, standardised studies.
各种免疫细胞已被认为是癌症患者的预后标志物。在本文中，我们对评估口腔癌组织浸润免疫细胞预后价值的研究进行了系统回顾和荟萃分析，并讨论了这些研究的报告质量。
我们进行了系统的文献检索，纳入了使用免疫组织化学和生存分析来评估肿瘤浸润 T 细胞、B 细胞、巨噬细胞、树突状细胞、肥大细胞和自然杀伤细胞在口腔癌中的预后价值的研究。我们对提供必要统计数据的研究进行了荟萃分析，并调查了研究对肿瘤标志物预后研究报告（REMARK）指南的遵循情况。
在确定的 1960 篇文章中，有 33 篇符合本系统综述的纳入标准，有 8 篇纳入荟萃分析。CD163+M2 巨噬细胞和 CD57+自然杀伤细胞是口腔癌患者生存的最有前途的预测因子。许多研究缺乏关于其设计和实施的重要信息。
研究设计和实施报告的不足使得难以就所提出的标志物得出可靠的结论。CD163+M2 巨噬细胞和 CD57+自然杀伤细胞的预后价值应在大型标准化研究中得到验证。
